Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...

Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...